CompletedPhase 1NCT03475056

cAd3-Marburg Vaccine in Healthy Adults

Studying Marburg hemorrhagic fever

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Melinda Hamer, M.D.
WRAIR Clinical Trials Center
Intervention: cAd3-Marburg vaccine(biological)
Enrollment: 40 enrolled
Eligibility: 18-50 years · All sexes
Timeline: 2018 – 2019

Study locations (1)

WRAIR Clinical Trials Center,, Silver Spring, Maryland, United States

Collaborators

US Military HIV Research Program

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03475056 on ClinicalTrials.gov

Other trials for Marburg hemorrhagic fever

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT06620003
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
Albert B. Sabin Vaccine Institute

See all trials for Marburg hemorrhagic fever →

← Back to all trials